These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 18265796)

  • 1. [New drugs; pegaptanib and ranibizumab].
    van Bronswijk H; Dubois EA; van Meurs JC; Cohen AF
    Ned Tijdschr Geneeskd; 2008 Jan; 152(2):82-4. PubMed ID: 18265796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.
    Takeda AL; Colquitt J; Clegg AJ; Jones J
    Br J Ophthalmol; 2007 Sep; 91(9):1177-82. PubMed ID: 17475698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegaptanib for wet macular degeneration.
    Fraunfelder FW
    Drugs Today (Barc); 2005 Nov; 41(11):703-9. PubMed ID: 16395411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
    Jeganathan VS; Verma N
    Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pegaptanib for neovascular age-related macular degeneration.
    Maberley D
    Issues Emerg Health Technol; 2005 Dec; (76):1-4. PubMed ID: 16544440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.
    Joeres S; Kaplowitz K; Brubaker JW; Updike PG; Collins AT; Walsh AC; Romano PW; Sadda SR
    Ophthalmology; 2008 Feb; 115(2):347-354.e2. PubMed ID: 17628685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology.
    Ip MS; Scott IU; Brown GC; Brown MM; Ho AC; Huang SS; Recchia FM;
    Ophthalmology; 2008 Oct; 115(10):1837-46. PubMed ID: 18929163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [VEGF inhibitors in ophthalmology].
    Thys J; Dupont G; Rakic JM
    Rev Med Liege; 2009; 64(5-6):323-6. PubMed ID: 19642468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice.
    van Wijngaarden P; Qureshi SH
    Clin Exp Optom; 2008 Sep; 91(5):427-37. PubMed ID: 18637105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Ciulla TA; Rosenfeld PJ
    Curr Opin Ophthalmol; 2009 May; 20(3):158-65. PubMed ID: 19417570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monotherapy of exudative age-related macular degeneration with ranibizumab in patients at cardiovascular risk. Advantages of ranibizumab compared to a combination with pegaptanib].
    Matthé E; Sandner D
    Ophthalmologe; 2011 Apr; 108(4):337-41. PubMed ID: 21181168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Introduction to the topic: anti-VEGF therapy in the management of AMD].
    Meyer CH
    Ophthalmologe; 2008 Feb; 105(2):123-4. PubMed ID: 18256843
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
    Waisbourd M; Loewenstein A; Goldstein M; Leibovitch I
    Drugs Aging; 2007; 24(8):643-62. PubMed ID: 17702534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H; Abrams P
    Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.
    Gupta B; Adewoyin T; Patel SK; Sivaprasad S
    Br J Ophthalmol; 2011 Mar; 95(3):386-90. PubMed ID: 20693484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial.
    Chang TS; Bressler NM; Fine JT; Dolan CM; Ward J; Klesert TR;
    Arch Ophthalmol; 2007 Nov; 125(11):1460-9. PubMed ID: 17998507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of wet age-related macular degeneration with vascular endothelial growth factor. A survey of a Cochrane review].
    Bloch SB; Larsen M
    Ugeskr Laeger; 2009 Nov; 171(47):3435-7. PubMed ID: 19925729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration.
    Semeraro F; Morescalchi F; Parmeggiani F; Arcidiacono B; Costagliola C
    Curr Vasc Pharmacol; 2011 Sep; 9(5):629-46. PubMed ID: 21470108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A view on new drugs for macular degeneration.
    Drug Ther Bull; 2007 Jul; 45(7):49-52. PubMed ID: 17718304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration.
    Bressler SB
    Ophthalmology; 2009 Oct; 116(10 Suppl):S1-7. PubMed ID: 19800534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.